Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
The pharma companies will bring quality products at competitive prices to consumers in Oman and help bring down the cost of healthcare
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
There is a need for the Ministry of Health to put it on the priority list and address the issues, which are numerous
Upon closing, the Quakertown business will become an independent company called Microsize
RNAstorm and DNAstorm RNA/DNA extraction kits will be sold exclusively through the Biotium website and authorized distributors
Subscribe To Our Newsletter & Stay Updated
